AstraZeneca drops an OX40 cancer drug candidate in Q4 pipeline cleanup
Q4 may have been a triumph in many respects, as AstraZeneca’s cancer drugs continue to carve out a bigger franchise for the company — crucial for its future. But there were also some big setbacks as the R&D group continues to hit and miss with its trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.